Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

About this update from Enveric Biosciences, Inc.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, being held on July 16, 2026, in Boston, MA. Joseph Tucker, Ph.D., CEO of Enveric, will participate in a Neuropsychiatry Fireside Chat to discuss current trends within the neuropsychiatry sector and the outlook for mental health drug development. Event Details: Event: Mind, Muscle & Vision Summit, Hosted by B. Riley Securities Agenda: Neuropsychiatry Fireside Chat Date & Time: July 16, 2026, 12:30-12:55 PM EDT Location: Abigail Adams Salon A, InterContinental Boston “We are excited to discuss the current trends in neuropsychiatry and demonstrate how EB-003, a unique neuroplastogen designed to not induce hallucinogenic effects, is positioned to address key challenges in mental health drug development,” said Joseph Tucker, Ph.D., CEO of Enveric. “With encouraging preclinical data driving us steadily toward IND submission and Phase 1 clinical entry, we look forward to sharing our momentum and unique mechanism of action with potential investors and strategic partners at the summit.” Enveric’s management team will also conduct one-on-one meetings with registered investors throughout the day to discuss the Company’s business strategy, recent corporate achievements, and upcoming clinical milestones. About Enveric Biosciences Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT2A and 5-HT1B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience. For more information, please visit www.enveric.com. Forward-Looking Statements This press release contains forward-looking statements and forward-looking information within the meaning of...

View stock analysis, news, and events for Enveric Biosciences, Inc.